ZPR1 rs2075290: What Your Genotype Means
The genetic variant rs2075290 is a single nucleotide polymorphism located in the ZPR1 locus, closely clustered with apolipoprotein genes including APOA5 and APOA4 on chromosome 11. Population studies associate this marker with slight shifts in circulating blood lipid levels, notably triglycerides, which play a role in long-term cardiovascular disease risk. However, current clinical evidence linking this individual variant directly to health outcomes remains limited and polygenic in nature.
What each genotype means
Typical lipid risk profile
This genotype represents the most common form of the ZPR1/APOA5-APOA4 locus in many populations. Research suggests this version is not associated with the increased predisposition to hypertriglyceridemia observed with the minor allele. Please consult with a healthcare provider to discuss your overall cardiovascular health and lipid management.
This is the most frequent genotype in European populations, carried by the majority of individuals.
Increased lipid risk marker
Carrying one copy of the minor allele at this locus has been associated in some studies with a predisposition to hypertriglyceridemia and potential cardiovascular risk. Because the evidence strength for this specific variant is limited, this result should be viewed as a statistical association rather than a diagnostic indicator. Discuss your lipid profile and cardiovascular risk factors with your clinician or a lipid specialist.
Carried by roughly 1 in 4 to 1 in 3 people of European ancestry, based on a minor allele frequency of approximately 0.15.
Elevated lipid risk marker
Carrying two copies of the minor allele is associated with a higher statistical predisposition to hypertriglyceridemia compared to those without the variant. As the evidence for this specific variant's clinical impact remains limited, it is important to interpret this in the context of your overall health, including diet, lifestyle, and other genetic factors. Please discuss your lipid levels and cardiovascular risk management with your healthcare provider.
This genotype is the least common, occurring in approximately 2% to 3% of individuals of European ancestry.
Genomic Context and the ZPR1 Locus
The single nucleotide polymorphism rs2075290 is situated on chromosome 11 within the ZPR1 gene (historically referred to as ZNF259). This region forms a critical genomic hub that sits in immediate proximity to the well-known APOA1/C3/A4/A5 gene cluster. Because these adjacent genes lie within a region of tight linkage disequilibrium, genetic variations in ZPR1 frequently segregate alongside functional regulatory changes affecting neighboring apolipoproteins. While rs2075290 is primarily classified as an intronic variant within ZPR1, its biological influence is frequently interpreted through its physical proximity to APOA5, a potent regulator of triglyceride clearance and intravascular lipid processing.
Biological Role of ZPR1 and Surrounding Genes
The ZPR1 gene encodes a highly conserved zinc finger protein that interacts with the survival motor neuron (SMN) complex and participates in fundamental cellular processes, including cell cycle progression, RNA processing, and cellular signaling. Despite this fundamental cellular role, extensive genome-wide association studies (GWAS) regularly identify ZPR1 single nucleotide polymorphisms in association with lipid traits. Researchers hypothesize that non-coding variants within ZPR1 may influence the transcriptional activity or enhancer loops controlling nearby apolipoprotein genes—particularly APOA5, which activates lipoprotein lipase to hydrolyze triglyceride-rich particles. Consequently, alterations in this genomic cluster can directly modulate circulating triglyceride levels.
Scientific Evidence and Cardiovascular Risk
Research across diverse cohorts has linked variation at the ZPR1 locus to differences in fasting triglycerides, metabolic traits, and downstream atherosclerotic cardiovascular risk. Nonetheless, the standalone scientific evidence for rs2075290 is categorized as limited. While large-scale meta-analyses and the EBI GWAS Catalog highlight multiple variants across the ZPR1-APOA5 cluster, individual common SNPs usually confer subtle, incremental shifts in lipid fractions rather than monogenic disease states. Hypertriglyceridemia and cardiovascular disorders are inherently polygenic, meaning that rs2075290 acts only as one small piece within a broader landscape composed of dozens of lipid-related genetic alleles, diet, lifestyle, and overall metabolic health.
Practical Implications and Clinical Perspective
Learning your rs2075290 genotype provides insight into inherited tendencies across lipid pathways, but it cannot diagnose any medical condition or predict whether you will develop heart disease. Standard fasting lipid panels—which directly measure triglycerides, LDL cholesterol, and HDL cholesterol—remain the definitive diagnostic tool for clinical risk assessment. If you carry alleles associated with higher triglyceride levels, evidence-based lifestyle choices such as regular aerobic physical activity, moderation of refined carbohydrates, and limiting alcohol intake remain cornerstone interventions. This genetic information should never replace clinical lipid monitoring or medical guidance from a qualified healthcare professional.
How common is this variant?
The minor allele frequency for rs2075290 is approximately 0.15 in populations of European ancestry, indicating that the heterozygous genotype is carried by roughly a quarter of individuals in these cohorts.
Frequently asked questions
Does having the rs2075290 risk allele mean I will develop high triglycerides?
No. The rs2075290 variant confers only a small, statistical predisposition toward higher triglyceride concentrations. Circulating lipid levels are primarily governed by dietary habits, body composition, exercise, and the cumulative impact of hundreds of other genetic variants.
What is the difference between ZPR1 and APOA5?
ZPR1 is a zinc finger gene involved in cell signaling and nuclear transport, whereas APOA5 encodes an apolipoprotein directly responsible for clearing triglycerides from the bloodstream. Because these two genes are physical neighbors on chromosome 11, genetic variations in ZPR1 often reflect regulatory impacts on APOA5.
Should I change my medication or cholesterol treatment based on this result?
No. Genetic variations such as rs2075290 should never be used to initiate, alter, or discontinue prescription medications. Any decisions regarding lipid-lowering therapies or cardiovascular risk management must be made in consultation with your doctor based on clinical laboratory tests.
How can I tell if this variant is actively affecting my health?
The only way to determine your current triglyceride and cardiovascular health status is through routine blood work, such as a fasting lipid panel. Genetic tests reveal inherited probabilities, whereas blood tests measure your actual, real-time metabolic physiology.
Sources & further reading
Educational information only, last refreshed 9/5/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs2075290?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29